https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2016-06-29 / J. Immunol. 2016 08;197(3):795-806
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2016-06-29 / J. Immunol. 2016 08;197(3):795-8062016-06-29 00:00:002019-02-15 08:48:41NK Cell Activation in the Antitumor Response Induced by IFN-α Dendritic Cells Loaded with Apoptotic Cells from Follicular Lymphoma Patients
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2016-06-27 / Cell. Mol. Immunol. 2018 02;15(2):135-145
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2016-06-27 / Cell. Mol. Immunol. 2018 02;15(2):135-1452016-06-27 00:00:002016-06-27 00:00:00HSP70L1-mediated intracellular priming of dendritic cell vaccination induces more potent CTL response against cancer
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2016-06-21 / Immunity 2016 06;44(6):1255-69
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2016-06-21 / Immunity 2016 06;44(6):1255-692016-06-21 00:00:002019-02-15 08:35:58Resistance Mechanisms to Immune-Checkpoint Blockade in Cancer: Tumor-Intrinsic and -Extrinsic Factors
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2016-06-20 / Hum Vaccin Immunother 2016 10;12(10):2523-2528
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2016-06-20 / Hum Vaccin Immunother 2016 10;12(10):2523-25282016-06-20 00:00:002019-02-15 08:49:43Dendritic cell vaccination in melanoma patients: From promising results to future perspectives
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2016-06-17 / J Clin Oncol 36, 2018 (suppl; abstr e24000)
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2016-06-17 / J Clin Oncol 36, 2018 (suppl; abstr e24000)2016-06-17 12:11:492019-07-17 12:12:15Anti-tumor efficacy of the Runx2-dendritic cell vaccine in triple-negative breast cancer in vitro.
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2016-06-17 / Oncoimmunology 2016 Aug;5(8):e1201625
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2016-06-17 / Oncoimmunology 2016 Aug;5(8):e12016252016-06-17 00:00:002016-06-17 00:00:00Ipilimumab administered to metastatic melanoma patients who progressed after dendritic cell vaccination
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2016-06-16 / J Drug Target 2016 11;24(9):865-877
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2016-06-16 / J Drug Target 2016 11;24(9):865-8772016-06-16 00:00:002019-02-15 09:18:22Thermosensitive liposomal cisplatin in combination with local hyperthermia results in tumor growth delay and changes in tumor microenvironment in xenograft models of lung carcinoma
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2016-06-13 / Cell Death Discov 2016;2:16039
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2016-06-13 / Cell Death Discov 2016;2:160392016-06-13 00:00:002016-06-13 00:00:00Comparison of biological effects of modulated electro-hyperthermia and conventional heat treatment in human lymphoma U937 cells
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
IOZK
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
IOZK2016-06-10 12:35:252019-02-10 12:36:00Fachbeitrag von Prof. Schirrmacher zur Effizienz und Effektivität der Krebsbehandlung, Wiener klinisches Magazin
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2016-06-09 / Expert Opin Biol Ther 2016 09;16(9):1113-23
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2016-06-09 / Expert Opin Biol Ther 2016 09;16(9):1113-232016-06-09 00:00:002019-02-15 08:32:44Progress of dendritic cell-based cancer vaccines for patients with hematological malignancies
